• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

INO-4800 DNA疫苗可诱导针对全球新冠病毒变异株的中和抗体和T细胞活性。

INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants.

作者信息

Andrade Viviane M, Christensen-Quick Aaron, Agnes Joseph, Tur Jared, Reed Charles, Kalia Richa, Marrero Idania, Elwood Dustin, Schultheis Katherine, Purwar Mansi, Reuschel Emma, McMullan Trevor, Pezzoli Patrick, Kraynyak Kim, Sylvester Albert, Mammen Mammen P, Tebas Pablo, Joseph Kim J, Weiner David B, Smith Trevor R F, Ramos Stephanie J, Humeau Laurent M, Boyer Jean D, Broderick Kate E

机构信息

Inovio Pharmaceuticals, Plymouth Meeting, PA, USA.

Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, PA, USA.

出版信息

NPJ Vaccines. 2021 Oct 14;6(1):121. doi: 10.1038/s41541-021-00384-7.

DOI:10.1038/s41541-021-00384-7
PMID:34650089
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8516974/
Abstract

Global surveillance has identified emerging SARS-CoV-2 variants of concern (VOC) associated with broadened host specificity, pathogenicity, and immune evasion to vaccine-induced immunity. Here we compared humoral and cellular responses against SARS-CoV-2 VOC in subjects immunized with the DNA vaccine, INO-4800. INO-4800 vaccination induced neutralizing antibodies against all variants tested, with reduced levels detected against B.1.351. IFNγ T cell responses were fully maintained against all variants tested.

摘要

全球监测已发现新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变异株（VOC），这些变异株具有更广泛的宿主特异性、致病性，并能逃避免疫接种诱导的免疫。在此，我们比较了接种DNA疫苗INO-4800的受试者针对SARS-CoV-2变异株的体液免疫和细胞免疫反应。接种INO-4800疫苗可诱导针对所有测试变异株的中和抗体，但针对B.1.351变异株的中和抗体水平有所降低。针对所有测试变异株，γ干扰素T细胞反应均完全得以维持。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7997/8516974/714dcd21b3cd/41541_2021_384_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7997/8516974/8c08cdd784fd/41541_2021_384_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7997/8516974/714dcd21b3cd/41541_2021_384_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7997/8516974/8c08cdd784fd/41541_2021_384_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7997/8516974/714dcd21b3cd/41541_2021_384_Fig2_HTML.jpg

相似文献

1
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants.INO-4800 DNA疫苗可诱导针对全球新冠病毒变异株的中和抗体和T细胞活性。
NPJ Vaccines. 2021 Oct 14;6(1):121. doi: 10.1038/s41541-021-00384-7.
2
Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.两剂蛋白亚单位疫苗 MVC-COV1901 初免后加强接种多剂 mRNA 疫苗可增强针对新型 SARS-CoV-2 变异株的体液和细胞免疫应答。
Microbiol Spectr. 2022 Oct 26;10(5):e0060922. doi: 10.1128/spectrum.00609-22. Epub 2022 Aug 25.
3
Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates.INO-4800 和 INO-4802 的联合加强疫苗方案增强并拓宽了非人类灵长类动物对 SARS-CoV-2 的免疫反应。
Vaccine. 2022 May 9;40(21):2960-2969. doi: 10.1016/j.vaccine.2022.03.060. Epub 2022 Apr 4.
4
Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination.接种 BNT162b2 疫苗后针对严重急性呼吸综合征冠状病毒 2 变异株和人类冠状病毒的体液和细胞免疫应答。
Clin Infect Dis. 2021 Dec 6;73(11):2000-2008. doi: 10.1093/cid/ciab555.
5
Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time.卫星五号疫苗接种后的纵向研究显示，随着时间的推移，SARS-CoV-2 中和抗体具有持久性，并且对病毒变异的中和逃逸能力降低。
mBio. 2022 Feb 22;13(1):e0344221. doi: 10.1128/mbio.03442-21. Epub 2022 Jan 25.
6
Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine.病例报告：BNT162b2 疫苗接种后两次 COVID-19 突破感染的体液和细胞免疫演变。
Front Immunol. 2022 Feb 23;13:790212. doi: 10.3389/fimmu.2022.790212. eCollection 2022.
7
A booster dose of an inactivated SARS-CoV-2 vaccine increases neutralizing antibodies and T cells that recognize Delta and Omicron variants of concern.一剂新冠病毒灭活疫苗加强针可增加中和抗体以及识别德尔塔和奥密克戎变异株的T细胞。
medRxiv. 2022 Feb 7:2021.11.16.21266350. doi: 10.1101/2021.11.16.21266350.
8
SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response.SARS-CoV-2 mRNA 疫苗 BNT162b2 引发一致的跨变体体液和细胞反应。
Emerg Microbes Infect. 2021 Dec;10(1):2235-2243. doi: 10.1080/22221751.2021.2004866.
9
An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.鼻内注射慢病毒加强针可增强正在减弱的、由mRNA疫苗诱导产生的、针对肺黏膜的SARS-CoV-2免疫力。
Mol Ther. 2022 Sep 7;30(9):2984-2997. doi: 10.1016/j.ymthe.2022.04.016. Epub 2022 Apr 27.
10
Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children.儿童中灭活疫苗诱导的 SARS-CoV-2 变异株特异性免疫。
mBio. 2022 Dec 20;13(6):e0131122. doi: 10.1128/mbio.01311-22. Epub 2022 Nov 16.

引用本文的文献

1
Next-Generation Vaccine Platforms: Integrating Synthetic Biology, Nanotechnology, and Systems Immunology for Improved Immunogenicity.下一代疫苗平台：整合合成生物学、纳米技术和系统免疫学以提高免疫原性
Vaccines (Basel). 2025 May 30;13(6):588. doi: 10.3390/vaccines13060588.
2
Advances in the Functionalization of Vaccine Delivery Systems: Innovative Strategies and Translational Perspectives.疫苗递送系统功能化的进展：创新策略与转化前景
Pharmaceutics. 2025 May 12;17(5):640. doi: 10.3390/pharmaceutics17050640.
3
A Narrative Overview of Coronavirus Infection: Clinical Signs and Symptoms, Viral Entry and Replication, Treatment Modalities, and Management.

本文引用的文献

1
Impact of SARS-CoV-2 variants on the total CD4 and CD8 T cell reactivity in infected or vaccinated individuals.新冠病毒变异株对感染或接种个体中总 CD4 和 CD8 T 细胞反应性的影响。
Cell Rep Med. 2021 Jul 20;2(7):100355. doi: 10.1016/j.xcrm.2021.100355. Epub 2021 Jul 2.
2
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.多种严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体可逃避疫苗诱导的体液免疫的中和作用。
Cell. 2021 Apr 29;184(9):2523. doi: 10.1016/j.cell.2021.04.006.
3
Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization.
冠状病毒感染的叙述性概述：临床体征和症状、病毒进入和复制、治疗方式和管理。
Curr Top Med Chem. 2024;24(21):1883-1916. doi: 10.2174/0115680266296095240529114058.
4
Genetic fusion of CCL11 to antigens enhances antigenicity in nucleic acid vaccines and eradicates tumor mass through optimizing T-cell response.CCL11 与抗原的基因融合增强了核酸疫苗的抗原性，并通过优化 T 细胞反应消除了肿瘤。
Mol Cancer. 2024 Mar 8;23(1):46. doi: 10.1186/s12943-024-01958-4.
5
COVID-19 Vaccines: Where Did We Stand at the End of 2023?COVID-19 疫苗：2023 年底我们处于什么位置？
Viruses. 2024 Jan 29;16(2):203. doi: 10.3390/v16020203.
6
Nanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models.基于纳米颗粒的 DNA 疫苗可预防女性临床前模型中的 SARS-CoV-2 变体。
Nat Commun. 2024 Jan 18;15(1):590. doi: 10.1038/s41467-024-44830-1.
7
Lipid nanoparticle-encapsulated DNA vaccine robustly induce superior immune responses to the mRNA vaccine in Syrian hamsters.脂质纳米颗粒包裹的DNA疫苗在叙利亚仓鼠中能强力诱导出比mRNA疫苗更优的免疫反应。
Mol Ther Methods Clin Dev. 2023 Dec 5;32(1):101169. doi: 10.1016/j.omtm.2023.101169. eCollection 2024 Mar 14.
8
Tracking the COVID-19 vaccines: The global landscape.追踪 COVID-19 疫苗：全球形势。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2191577. doi: 10.1080/21645515.2023.2191577. Epub 2023 Mar 30.
9
From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era.从免疫原到 COVID-19 疫苗：后疫情时代的前景。
Biomed Pharmacother. 2023 Feb;158:114208. doi: 10.1016/j.biopha.2022.114208. Epub 2023 Jan 2.
10
Optimization of In Vivo Electroporation Conditions and Delivery of DNA Vaccine Encoding SARS-CoV-2 RBD Using the Determined Protocol.使用确定的方案优化体内电穿孔条件并递送编码SARS-CoV-2刺突蛋白受体结合域的DNA疫苗。
Pharmaceutics. 2022 Oct 22;14(11):2259. doi: 10.3390/pharmaceutics14112259.
SARS-CoV-2 变异株 P.1 对抗体中和的抵抗力增强。
Cell Host Microbe. 2021 May 12;29(5):747-751.e4. doi: 10.1016/j.chom.2021.04.007. Epub 2021 Apr 18.
4
Antibody evasion by the P.1 strain of SARS-CoV-2.SARS-CoV-2 P.1 株的抗体逃逸。
Cell. 2021 May 27;184(11):2939-2954.e9. doi: 10.1016/j.cell.2021.03.055. Epub 2021 Mar 30.
5
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.传染性 SARS-CoV-2 B.1.1.7 和 B.1.351 变体对中和抗体的敏感性。
Nat Med. 2021 May;27(5):917-924. doi: 10.1038/s41591-021-01318-5. Epub 2021 Mar 26.
6
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.mRNA-1273疫苗引发的血清中和活性。
N Engl J Med. 2021 Apr 15;384(15):1468-1470. doi: 10.1056/NEJMc2102179. Epub 2021 Mar 17.
7
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.科维希尔德腺病毒载体新冠疫苗（ChAdOx1 nCoV-19）对 B.1.351 变异株的有效性。
N Engl J Med. 2021 May 20;384(20):1885-1898. doi: 10.1056/NEJMoa2102214. Epub 2021 Mar 16.
8
Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7.社区检出的 SARS-CoV-2 谱系 B.1.1.7 病例死亡率增加。
Nature. 2021 May;593(7858):270-274. doi: 10.1038/s41586-021-03426-1. Epub 2021 Mar 15.
9
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.COVID-19 用 Ad26.COV2.S 疫苗的免疫原性。
JAMA. 2021 Apr 20;325(15):1535-1544. doi: 10.1001/jama.2021.3645.
10
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.SARS-CoV-2 变体 B.1.351 和 B.1.1.7 的抗体抗性。
Nature. 2021 May;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8.